Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure

Nir Eyal, Marc Lipsitch, Peter G. Smith

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care.

Original languageEnglish (US)
Pages (from-to)1752-1756
Number of pages5
JournalThe Journal of infectious diseases
Volume221
Issue number11
DOIs
StatePublished - May 11 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Immunology and Allergy

Keywords

  • coronavirus
  • ethics
  • human challenge studies
  • randomized controlled trials
  • risk-taking
  • vaccines

Fingerprint Dive into the research topics of 'Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure'. Together they form a unique fingerprint.

  • Cite this